Selank for anxiety: what the actual research says

What did @jackson_peps actually say?

The creator claims selank is "the greatest invention for anxiety ever," positions it as a side-effect-free alternative to SSRIs, and argues that injectable selank is more bioavailable than intranasal administration. They also state the peptide works on GABA "but not directly," that this prevents receptor downregulation, and that it carries zero addiction risk. They recommend doses between 250 and 500 micrograms and close with a plug for their bio link as a source.

There is a lot to unpack here. Some of what they said has a reasonable basis in the existing research. Some of it is speculation presented as settled fact. And the injection-versus-intranasal claim in particular contradicts how selank was actually developed and studied.

Does the science back this up?

Partially, and with serious caveats. Selank is a synthetic heptapeptide derived from tuftsin, originally developed at the Institute of Molecular Genetics in Russia. Most of the published human data comes from Russian clinical trials, which have significant methodological limitations and have not been replicated in large Western RCTs.

The GABA-modulating mechanism the creator describes is real, at least in animal models. Research by Seredenin and Voronina (2009, Eksperimental'naya i Klinicheskaya Farmakologiya) identified anxiolytic effects potentially linked to GABAergic modulation without direct agonist binding, which would theoretically reduce the receptor downregulation problem seen with benzodiazepines. A 2011 study by Kolik et al. in the same journal found selank influenced GABA-A receptor subunit expression in rodents differently than diazepam. That is genuinely interesting. But rodent pharmacology does not automatically translate to humans, and the creator presents this as confirmed fact rather than preliminary evidence.

What did they get wrong (or right)?

The intranasal claim is where this goes most clearly off the rails. Selank was specifically developed as an intranasal formulation. The original Russian clinical work, including studies reviewed by Zozulya et al. (2001, CNS Drug Reviews), was conducted using intranasal delivery because the peptide degrades rapidly in the bloodstream and intranasal administration allows for direct access to the central nervous system via the olfactory pathway, bypassing first-pass degradation. The creator dismisses this as "rumors" and insists injections are superior based on personal anecdote and social circle feedback. That is not evidence.

On the addiction and receptor downregulation point, they are directionally correct based on available mechanistic data. Selank does not appear to act as a direct GABA-A agonist the way benzodiazepines do, which is a meaningful distinction. Calling it completely addiction-free is an overclaim given the absence of long-term human safety trials, but the mechanism is legitimately different from classic GABAergic drugs.

Comparing selank to SSRIs and calling SSRI side effects "strong" while implying selank has none is misleading. Selank has not been studied in head-to-head trials against SSRIs. We simply do not have the data to make that comparison responsibly.

What should you actually know?

Selank is a research peptide with an interesting but underdeveloped evidence base. It is not FDA-approved for any condition. The studies that exist are mostly small, mostly Russian, and mostly in animals or populations not representative of a general Western audience. That does not mean it is worthless, but it does mean you are taking on real uncertainty when using it.

The intranasal versus injectable debate matters practically. If the peptide was designed for intranasal use based on its pharmacokinetic profile, rejecting that delivery method because "injections feel better" is not a sound rationale. CNS peptide delivery is complicated. The olfactory route exists for a reason.

The bio-link sourcing pitch at the end of this video should raise a flag. Recommending a specific vendor for a compound you are also endorsing is a conflict of interest, and unregulated peptide sources vary wildly in purity and concentration. Anyone considering selank should be working with a licensed clinician, not sourcing from a TikTok bio link.

Bottom line on @jackson_peps's selank take

The mechanistic framing around GABA is not entirely wrong, and selank does have genuine research interest behind it. But the injection-over-intranasal claim contradicts the compound's development history, the SSRI comparison is irresponsible without trial data, and presenting personal experience as pharmacological evidence is a recurring problem in peptide content. The research is early. The confidence in this video is not earned by the evidence.